1-(4-(benzylbenzamid0) -benzyl) azetidine-3-carboxylic acid derivatives and related compounds as SlP receptor modulators for the treatment of immune disorders

Details for Australian Patent Application No. 2008302746 (hide)

Owner Epix Pharmaceuticals, Inc. Amgen Inc.

Inventors Neira, Susana C.; Yu, Xiang; Burli, Roland; Cee, Victor; Lanman, Brian

Agent Wrays

Pub. Number AU-A-2008302746

PCT Pub. Number WO2009/038759

Priority 60/994,812 20.09.07 US

Filing date 19 September 2008

Wipo publication date 26 March 2009

International Classifications

C07D 205/04 (2006.01) Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom

A61K 31/397 (2006.01) - having four-membered rings, e.g. azetidine

A61K 31/4427 (2006.01) - containing further heterocyclic ring systems

A61P 37/06 (2006.01) Drugs for immunological or allergic disorders

C07D 401/10 (2006.01) Heterocyclic compounds containing two or more hetero rings

Event Publications

1 April 2010 PCT application entered the National Phase

  PCT publication WO2009/038759 Priority application(s): WO2009/038759

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008302747-Human GM-CSF antigen binding proteins

2008302744-Solid forms comprising N- (5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-m orpholin4-yl-ethoxy)imidazo[2,1-b][1,3]benzothi azol-2-yl]phenyl}urea, compositions thereof, and uses therewith